Alkermes PLC | Cash Flow

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Net Income before Extraordinaries
17,649.00
30,061.00
227,163.00
208,444.00
157,945.00
139,311
Depreciation, Depletion & Amortization
70,765.00
98,087.00
85,596.00
94,256.00
98,523.00
103,660
Other Funds
271.00
19,527.00
28,576.00
9,238.00
16,433.00
131,729
Funds from Operations
87,923.00
279.00
122,341.00
36,599.00
24,071.00
106,701
Changes in Working Capital
4,298.00
10,860.00
81,981.00
27,203.00
4,881.00
7,420
Net Operating Cash Flow
92,221.00
11,139.00
40,360.00
63,802.00
19,190.00
99,281
Capital Expenditures
19,054.00
33,651.00
52,877.00
43,657.00
51,300.00
Sale of Fixed Assets & Businesses
52.00
44,365.00
50,501.00
194.00
162.00
Purchase/Sale of Investments
46,364.00
274,111.00
41,110.00
170,706.00
32,782.00
Net Investing Cash Flow
65,366.00
263,397.00
43,486.00
127,243.00
18,356.00
Issuance/Reduction of Debt, Net
5,060.00
6,750.00
6,750.00
69,242.00
3,000.00
Net Financing Cash Flow
43,746.00
308,760.00
40,891.00
58,172.00
4,084.00
Net Change in Cash
70,601.00
56,502.00
42,955.00
5,269.00
4,918.00
Free Cash Flow
73,167.00
22,512.00
93,237.00
107,459.00
32,110.00
Deferred Taxes & Investment Tax Credit
15,393.00
19,192.00
37,580.00
9,689.00
7,234.00
10,623
Change in Capital Stock
49,077.00
295,983.00
19,065.00
20,308.00
23,517.00

About Alkermes

View Profile
Address
Connaught House
Dublin Dublin D04 C5Y6
Ireland
Employees -
Website http://www.alkermes.com
Updated 07/08/2019
Alkermes Plc IS a biopharmaceutical company, which engages in the development, research, and commercialization of medicines that are designed to address unmet medical needs of patients in major therapeutic areas. It operates through the following geographical segments: U. S.